Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson’s Disease
We are pleased to announce the completion of the last patient visit in this Phase III study, which represents an important milestone for Pharma Two
Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors
Mr. Berkowitz brings decades of experience in the global healthcare supply chain, having previously held executive committee and other senior operating roles at UnitedHealth Group,
Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer
Dr. Oren Has 25 Years’ Experience in Global Drug Development Leadership; Proven Track Record in PD REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) — Pharma
Pharma Two B Appoints David S. Tierney, M.D. as the Company’s Chief Executive Officer
Rehovot, Israel – February 18, 2020 – Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson
First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson’s Disease
Based on positive data from a Phase IIb pivotal study suggesting that P2B001 may offer effective therapy with minimal side effects for early stage Parkinson’s
Pharma Two B Ltd. Closes $30 Million Financing Round
REHOVOTH, Israel, February 27, 2017 — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it
We at PharmaTwoB are
striving to make your
life better by developing
innovative, products
based on previously
approved drugs.